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Introduction
In the field of cancer treatment, complementary and alter-
native medicine (CAM) is used as an adjunct therapy to con-
ventional medicine. Uses of CAM in cancer patients is aimed 
to relieve or prevent cancer-related symptoms [1], to treat 
cancer itself (similar to chemotherapy and radiotherapy) [2], 
and to impart a patient sense of active involvement in cancer 
treatment [3]. Despite insufficient scientific evidence, the use 
of CAM is increasing worldwide, and up to 80% of cancer pa-
tients are reported to use it [4]. In Korea, a multicenter study 
reported that more than 50% of cancer patients utilized CAM. 
In contrast with Western countries, dietary supplements, such 
as health functional foods (HFFs), are the most widely used 
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among the various types of CAM in Korea [5]. 
As interest in the use of the HFFs increase in cancer pa-
tients, safety concerns about these treatments are also in-
creasing [6]. Most individuals believe that HFFs are not harmful 
because they were made from natural materials [7]. However, 
some HFFs have been reported to produce serious side effects, 
such as hepatic and renal failure, cause harmful interactions 
with prescription drugs, and reduce the efficacy of other drugs 
[8,9]. Particularly, in the case of natural foods not approved by 
the Korean Food and Drug Administration (KFDA), food safety 
might be problematic. Considering these potential problems, 
cancer patients should receive counsel from health care pro-
fessionals regarding the use of HFFs, although most of them 
do not [10,11].
As an adjunct to cancer treatment, the use of HFFs seems to 
be increasing. However, little is known about the use of HFFs 
among cancer patients in Korea. It is essential to determine 
the exposure rate of HFFs and factors influencing preferences 
for HFFs used among cancer patients. The aims of this study 
were to investigate the exposure rate of HFFs used among 
gastrointestinal (GI) cancer patients and to examine any rela-
tionships between socio-demographics and disease-related 
characteristics with HFFs used. 
Materials and Methods
Study design and subjects
This was a cross-sectional survey using a questionnaire dis-
tributed and collected by hospital personnel to GI cancer pa-
tients who visited the out-patient department or were admit-
ted to Severance Hospital. All enrolled patients were followed-
up at the Department of Gastroenterology, were greater than 
20 years of age and had been radiologically or histologically 
diagnosed with GI cancer. Between November 4th, 2012 and 
November 24th, 2012, 126 patients (79 male, 47 female) were 
enrolled. The study protocol and questionnaire were approved 
by the Institutional Review Board of Severance Hospital, and 
written informed consent was obtained from each patient be-
fore enrollment.
Survey 
Based on a previous study [12], the contents of the ques-
tionnaire were prepared by a clinical dietitian and several med-
ical doctors who collaborated on this study. The questionnaire 
included four questions on socio-demographic characteristics 
(gender, age, educational status, average income per month), 
three questions on disease-related characteristics (site of can-
cer, date of diagnosis, and current cancer treatment), a number 
of questions related to HFF use (type of HFFs, duration of use, 
cost, route of obtainment, reason for use) and three questions 
on patient response to HFF use (recognizable changes after 
use, concerns related to HFFs, plan about further use). There 
was a list of HFFs that subjects could select. Participants were 
able to choose multiple items that they had used more than 
once since their cancer diagnosis. We referred to the KFDA 
website [13] in order to compose the HFF list and also included 
some folk remedies which are known to be widely used in 
Korea. At the end of the list, there were free-text boxes for 
respondents to add any HFFs, or folk remedies which were not 
included in the pre-coded list.
Data analysis and statistical methods
Binary logistic regression and Chi-squared tests were used 
to analyze the socio-demographic and disease-related factors 
predicting HFF use. A p-value less than 0.05 was considered 
to indicate statistical significance. All data analyses were per-
formed using SPSS (version 18.0, SPSS Inc., Chicago, IL, USA).
Results
Patient characteristics and HFF use
Table 1 shows participants` socio-demographic character-
istics and disease-related characteristics. The majority of par-
ticipants were male (n = 79; 62.7%) and between 61 and 70 
years of age (n = 53; 42%). High school was the highest level 
of education of most respondents (n = 50; 42.7%). Thirty-four 
percent of patients earned between 1 and 3 million Korean 
won (KRW) per month, which accounted for the largest group 
of patients (34.2%). With regard to disease-related character-
istics, pancreatobiliary cancer was the most common cancer 
among the enrolled patients (n = 72; 56.7%). Fifty-seven 
patients (45.2%) had been diagnosed for less than 6 months. 
Ninety-one patients (72.2%) were undergoing chemotherapy 
at the time of the survey, and 22 patients (17.5%) were under-
going radiotherapy.
Over half of all the patients (n = 67; 53.2%) used HFFs 
(Table 1). The relationship between HFF use and participants` 
characteristics was analyzed, and it was shown that the same 
proportion of male and female participants used HFFs (n = 42; 
53.2% vs. n = 25; 53.2%). None of the characteristics showed 
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a statistically significant difference in HFF use on bivariate 
analysis. According to age, average monthly income, and 
length of time since diagnosis, patients who were younger, 
had a higher income or a longer duration of disease trended to 
Table 1. Characteristics of the participants
Characteristic Participant no. (%) HFF users (%) Bivariate OR (95% CI); significance
Gender
Male 79 (62.7) 42 (53.2) 1.0 (0.5-2.0) ; 0.998
Female 47 (37.3) 25 (53.2) Reference
Age, yr
<61 47 (37.3) 27 (57.4) 1.6 (0.6-4.1) ; 0.356
61-70 53 (42) 28 (52.8) 1.3 (0.5-3.3) ; 0.577
≥71 26 (20.6) 12 (46.2) Reference
Highest level of education*
Elementary school 15 (12.8) 9 (60.0) 1.5 (0.4-5.4) ; 0.537
Middle school 26 (22.2) 11 (42.3) 0.7 (0.2-2.2) ; 0.578
High school 50 (42.7) 29 (58.0) 1.4 (0.5-3.6) ; 0.506
College / University 26 (22.2) 13 (50.0) Reference
Average income per month (10,000 KRW)† 
<100 37 (32.5) 18 (48.6) 0.5 (0-5.7) ; 0.556
100-300 39 (34.2) 22 (56.4) 0.6 (0.1-7.7) ; 0.731
300-500 31 (27.2) 16 (51.6) 0.5 (0-6.5) ; 0.622
500-1000 4 (3.5) 3 (75.0) 1.5 (0.1-40.6) ; 0.810
>1000 3 (2.6) 2 (66.7) Reference
Cancer type‡
Stomach 8 (6.3) 5 (62.5) 3.3 (0.4-30.7) ; 0.288
Pancreatobiliary 72 (56.7) 36 (50.0) 2.0 (0.3-11.6) ; 0.440
Liver 25 (19.7) 14 (56.0) 2.8 (0.4-18.4) ; 0.283
Colorectal 16 (12.6) 10 (62.5) 3.3 (0.5-24.0) ; 0.232
Others§ 6 (4.7) 2 (33.3) Reference
Months since diagnosis
<6 57 (45.2) 26 (45.6) 0.5 (0.3-1.3) ; 0.200
6-12 30 (23.8) 18 (60.0) 1.0 (0.4-2.8) ; 0.931
>12 39 (31) 23 (59.0) Reference
Current chemotherapy
Yes 91 (72.2) 48 (52.7) 0.9 (0.4-2.1) ; 0.877
No 35 (27.8) 19 (54.3) Reference
Current radiotherapy
Yes 22 (17.5) 13 (59.1) 1.3 (0.5-3.4) ; 0.541
No 104 (82.5) 54 (51.9) Reference
All participants 126 (100) 67 (53.2) 
HFFs: health functional foods, OR: odds ratio, CI: confidence interval, KRW: Korean won. 
*Nine participants did not answer the question about their highest level of education– odds ratio computed for 117 participants only; †There were 12 non-
responses on the question about average income per month – odds ratio calculated for only 114 participants; ‡One participant had double primary cancer (stomach 
cancer and hepatocellular carcinoma); §These include four ampulla of Vater cancers and one gastrointestinal stromal tumor (GIST).
Kang HP et al.
http://e-cnr.org http://dx.doi.org/10.7762/cnr.2013.2.1.1922
use HFFs more frequently, but the difference was not statisti-
cally significant. Because of these results, none of the charac-
teristics could be included in multivariate analysis. Therefore, it 
was not possible to calculate the multivariate odds ratio. 
Types of specific HFF used
Every HFF used by participants at least once was included 
in the analysis and is shown in Table 2. The most commonly 
used HFF was vitamin complex (n = 20; 16%), followed by red 
ginseng (n = 15; 12%), sweet wormwood (Artemisia annua) 
(n = 11; 8.8%), vitamin C (n = 8; 6.4%) and chaga mushroom 
(Inonotus obliquus) (n = 8; 6.4%), with sweet wormwood and 
chaga mushroom being natural foods and the others being 
dietary ingredients approved by the KFDA as dietary supple-
ments.
Route of obtainment and concerns about HFF use
Forty-four percent of patients who use HFFs obtained these 
materials as a gift (n = 30; 44.1%) (Table 3). Other patients ob-
tained HFFs from a health food store or grocery store (n = 20; 
29.4%). The expectation of a synergistic effect in combination 
with conventional cancer therapy was the most common rea-
son for using HFFs (n = 33; 40.7%), followed by recommenda-
tion from family members, friends, or other cancer patients (n 
= 23; 28.4%). In terms of recognizable change after use, 42.6 
% of patients thought nothing changed after using HFFs (n 
= 29). Seventeen patients (26.6%) expressed concerns about 
using HFF, as it was against their physician`s recommendations 
(n = 7; 36.8%), and lack of scientific evidence about the ef-
ficacy and safety of HFFS was another concern of patients (n 
= 4; 21.1%). As to the question of further use of HFFs, 63.3% 
of patients planned to consult with their physician about the 
issue and follow their doctor’s recommendation (n = 38), and 
33.3% planned to continue to use HFFs (n = 20).
Discussion
Fifty-three percent of GI cancer patients enrolled in this 
study used HFFs at the time of the survey. This is a higher per-
centage than that in a report from Western countries (16.8%) 
[14] but lower than data from a previous study conducted in 
Korea (78.1%) [15]. There were no significant differences in 
the use of HFFs according to socio-demographic or disease-
related factors. Even though it was not statistically significant, 
patients who were younger, had a higher income, or a longer 
duration of cancer tended to more commonly use HFFs. A 
previous study revealed that HFF users tend to be younger (less 
than 50 years of age), female patients with a higher socioeco-
nomic status and a longer duration of disease [14], whereas 
another study showed no differences between HFFs users and 
non-users according to patient characteristics [15]. Several 
Korean studies have shown that younger cancer patients are 
more likely to use HFFs [16-18]. 
The most commonly used HFF was vitamin complex, fol-
lowed by red ginseng and sweet wormwood (Artemisia annua). 
As in a previous study [15,19], frequently used HFFs in this 
survey could be categorized as ‘Vitamins/Minerals’ (i.e., vitamin 
complex, vitamin C and calcium) and ‘Natural materials’ (i.e., 
mushrooms, vegetables and herbs). 
The pancreatobiliary cancer group seemed to use vari-
ous types of HFFs listed in this study. However, there was no 
statistical evidence regarding which specific kinds of HFFs 
GI cancer patients choose according to their cancer site. In 
terms of the site of cancer, the pancreatobiliary cancer group 
comprised the majority of participants (56.7%), which is dif-
ferent from previously reported cancer studies in Korea [20]. 
This may be the result of the short enrollment period and the 
relatively small sample size. As such, participants in this study 
are not representative of all cancer patients in Korea. Despite 
these limitations, this study still has some value as a prelimi-
nary study.
In terms of the reason for use of HFFs, the majority of 
participants expected some synergistic effect between their 
traditional cancer treatment and the use of HHFs or had 
started using HFFs based on a recommendation from family 
members or acquaintances. After using HFFs, 42.6% of users 
experienced no subjective changes, whereas 23.5% and 20.6% 
felt less anxious and less tired about their cancer. However, 
there is still little scientific evidence to support such claims. 
Approximately one-quarter of all responders worried about 
using HFFs. A major concern was ‘going against physician`s 
recommendations,’ especially given that 63.3% of respon-
dents wanted to consult with their physicians and follow their 
recommendations. However, health-care professionals tend to 
devalue HFF usage [15], which leads to cancer patients rarely 
consulting with health-care professionals about the issue [21]. 
Thus, openness and a flexible attitude toward HFFs and more 
interest in education about HFF use is needed for health-care 
professionals who work with cancer patients. 
Overall, more than 50% of GI cancer patients reported hav-
ing used HFFs, and the exposure rate to HFFs is anticipated to 
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Table 2. Frequencies of use for specific HFFs and use by cancer type
Name (scientific name) Number ofusers (%)
Number of users by cancer site (%)*
Stomach Pancreatobiliary Liver Colorectal Other cancers†
HFFs approved by KFDA
Aloe (Aloe arborescens Mill)  1 (0.8) - -  1 (100.0) - -
Black mushroom (Lentinula edodes)  1 (0.8) -  1 (100.0) - - -
Calcium  1 (0.8) - - -  1 (100.0) -
Dietary fiber  1 (0.8) - - -  1 (100.0) -
Enzyme foods  6 (4.8) -  6 (100.0) - - -
Fermented soy-bean powder  1 (0.8) -  1 (100.0) - - -
Ginseng  2 (1.6) - - -  1 (50.0)  1 (50.0)
Glucosamine  4 (3.2) -  3 (75.0) -  1 (25.0) -
Iron supplement  1 (0.8)  1 (100.0) - - - -
Omega-3  4 (3.2) -  2 (50.0)  1 (25.0)  1 (25.0) -
Onion extract  2 (1.6) -  1 (50.0)  1 (50.0) - -
Oriental raisin tree fruit (Hovenia dulcis)  4 (3.2) -  1 (25.0)  3 (75.0) - -
Red ginseng  15 (12)  1 (6.7)  6 (40.0)  4 (26.7)  3 (20.0)  1 (6.7)
Reishi mushroom (Ganoderma lucidum)  2 (1.6) -  1 (50.0) -  1 (50.0) -
Sangwhang mushroom (Phellinus Linteus)  3 (2.4) - - -  3 (100.0) -
Vegetable worms (Cordyceps militaris)  1 (0.8) - - - -  1 (100.0)
Vitamin C  8 (6.4) -  4 (50.0) -  4 (50.0) -
Vitamin complex  20 (16)  1 (5.0)  9 (45.0)  4 (20.0)  4 (20.0)  2 (10.0)
Natural food not approved by KFDA
Black garlic extract  4 (3.2) -  2 (50.0)  2 (50.0) - -
Capillary wormwood (Artemisia capillaris)  1 (0.8) -  1 (100.0) - - -
Chaga mushroom (Inonotus obliquus)  8 (6.4)  1 (12.5)  5 (62.5)  1 (12.5)  1 (12.5) -
Chinese osage orange (Cudrania tricuspidata)  1 (0.8) -  1 (100.0) - - -
Colostrums powder  1 (0.8) - -  1 (100.0) - -
Dandelion (Taraxacum platycarpum Dahlst)  4 (3.2) -  2 (50.0)  1 (25.0)  1 (25.0) -
Fresh grinded dry meal  1 (0.8) -  1 (100.0) - - -
Green vegetable juice  3 (2.4) -  1 (33.3)  1 (33.3)  1 (33.3) -
Hooker chives (Allium hookeri)  1 (0.8) -  1 (100.0) - - -
Japanese elm (Ulmus davidiana var. japonica)  2 (1.6) -  2 (100.0) - - -
Mistletoe (Viscum album)  4 (3.2) -  2 (50.0) -  2 (50.0) -
Orostachys japonicus water extracts  2 (1.6) -  2 (100.0) - - -
Spotted spurge (Ceramium kondoi)  1 (0.8) -  1 (100.0) - - -
Sweet wormwood (Artemisia annua)  11 (8.8) -  8 (72.7)  1 (9.1)  1 (9.1)  1 (9.1)
Vegetable decoction  4 (3.2)  1 (25.0)  3 (75.0) - - -
Any HFFs & HSFs      125  5 (4.0)  67 (53.6)  21 (16.8)  26 (20.8)  6 (4.8)
KFDA: Korea Food and Drug Administration, HFFs: health functional foods, HSFs: health supplementary foods. 
*Percentages refer to the proportion of users of each HFF from within each cancer type; †These include four ampulla of Vater cancers and one gastrointestinal 
stromal tumor (GIST).
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grow. Patients who were younger, had a higher income, or had 
a longer cancer duration tended to more commonly use HFFs. 
More basic scientific data and educational materials are re-
quired for both health-care professionals and cancer patients. 
A larger sample and size-controlled groups representing each 
cancer type will continue to be recruited for participation in 
this survey.
Table 3. Questions about HFF use and patient stance on their use
Questions* Number (%)
Route of obtainment
Bought directly at a health food store, mall, or grocery store  20 (29.4)
From someone as a gift  30 (44.1)
Through mail order or on the internet  6 (8.8)
Prescription by hospital doctor  8 (11.8)
Others†  4 (5.9)
Reason for use 
Expectation of synergistic effect in combination with conventional cancer therapy  33 (40.7)
Recommendation from family members, friends, or other cancer patients  23 (28.4)
Already had started taking HFFs before the diagnosis was made  10 (12.3)
Information from TV, magazine, newspaper or internet news  7 (8.6)
Information from internet community related to cancer treatment  4 (4.9)
To eliminate anxiety about cancer itself  1 (1.2)
Others‡  3 (3.7)
Recognizable changes after use
Cancer-related symptoms are relieved  7 (10.3)
Feel better and less tired  14 (20.6)
Anxiety about cancer is decreased  16 (23.5)
Nothing changed significantly  29 (42.6)
Others§  2 (2.9)
Presence of concerns related to HFFs  17 (26.6)
Lack of scientific evidence about efficacy and safety  4 (21.1)
Going against my physician` s recommendation  7 (36.8)
Delay of conventional cancer treatment due to adverse effect of HFFs  1 (5.3)
Experience of symptoms related to adverse effect of HFFs  3 (15.8)
Cost  4 (21.1)
Others  0 (0)
Plan about further use
Continue to use  20 (33.3)
Stop taking HFFs  0 (0)
Consult with my physician and follow the recommendation  38 (63.3)
Othersll  2 (3.3)
HFFs: health functional foods.
*Each question allowed participants to choose multiple responses: †This includes three ‘I made it myself from natural materials’ and one ‘Offered free at nursing 
home’ responses; ‡Includes options of ‘Doctor’s recommendation,’ ‘To control the treatment-related symptoms’ and ‘no response’; §Includes ‘Suffered discomfort 
symptoms’ and ‘no response’; llIncludes ‘Confused.’
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